Generic Tosymra Availability
Last updated on Apr 10, 2025.
Tosymra is a brand name of sumatriptan, approved by the FDA in the following formulation(s):
TOSYMRA (sumatriptan - spray;nasal)
-
Manufacturer: TONIX MEDS
Approval date: January 25, 2019
Strength(s): 10MG/SPRAY [RLD]
Is there a generic version of Tosymra available?
No. There is currently no therapeutically equivalent version of Tosymra available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tosymra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Formulations comprising triptan compounds
Patent 10,603,305
Issued: March 31, 2020
Inventor(s): Gandhi Rajesh & Manikonda Sreekanth & Jana Arun & Kunte Sameer Shrinivas
Assignee(s): Upsher-Smith Laboratories, LLCThe invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tvalue of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.
Patent expiration dates:
- June 16, 2030✓✓
- June 16, 2030
-
Formulations comprising triptan compounds
Patent 11,337,962
Issued: May 24, 2022
Inventor(s): Gandhi; Rajesh et al.
Assignee(s): Upsher-Smith Laboratories, LLC (Maple Grove, MN)The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T.sub.max value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a T.sub.max substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.
Patent expiration dates:
- June 16, 2030✓✓
- June 16, 2030
-
Formulations comprising triptan compounds
Patent 12,090,139
Issued: September 17, 2024
Inventor(s): Gandhi; Rajesh et al.
Assignee(s): TONIX MEDICINES, INC. (Chatham, NJ)The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T.sub.max value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a T.sub.max substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.
Patent expiration dates:
- June 16, 2030✓
- June 16, 2030
-
Alkylglycoside compositions for drug administration
Patent 8,268,791
Issued: September 18, 2012
Inventor(s): Maggio Edward T.
Assignee(s): Aegis Therapeutics, LLC.The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Patent expiration dates:
- May 9, 2026✓
- May 9, 2026
-
Compositions for drug administration
Patent 8,440,631
Issued: May 14, 2013
Inventor(s): Maggio Edward T.
Assignee(s): Aegis Therapeutics, LLCThe present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Patent expiration dates:
- May 9, 2026✓✓
- May 9, 2026
-
Formulations comprising triptan compounds
Patent 9,211,282
Issued: December 15, 2015
Inventor(s): Gandhi Rajesh & Manikonda Sreekanth & Jana Arun & Kunte Sameer Shrinivas
Assignee(s): DR. REDDY'S LABORATORIES LTD.The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tvalue of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.
Patent expiration dates:
- July 19, 2031✓✓
- July 19, 2031
-
Compositions for drug administration
Patent 9,283,280
Issued: March 15, 2016
Inventor(s): Maggio Edward T.
Assignee(s): Aegis Therapeutics, LLCThe present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Patent expiration dates:
- May 9, 2026✓
- May 9, 2026
-
Formulations comprising triptan compounds
Patent 9,610,280
Issued: April 4, 2017
Inventor(s): Gandhi Rajesh & Manikonda Sreekanth & Jana Arun & Kunte Sameer Shrinivas
Assignee(s): DR. REDDY'S LABORATORIES LIMITEDThe invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tvalue of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.
Patent expiration dates:
- June 16, 2030✓✓
- June 16, 2030
-
Formulations comprising triptan compounds
Patent 9,974,770
Issued: May 22, 2018
Inventor(s): Gandhi Rajesh & Manikonda Sreekanth & Jana Arun & Kunte Sameer Shrinivas
Assignee(s): DR. REDDY'S LABORATORIES LTD.The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tvalue of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tsubstantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.
Patent expiration dates:
- June 16, 2030✓✓
- June 16, 2030
More about Tosymra (sumatriptan)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antimigraine agents
- Breastfeeding
- En español
Patient resources
Other brands
Imitrex, Zembrace SymTouch, Onzetra Xsail, Sumavel DosePro, ... +2 more
Professional resources
Other brands
Imitrex, Zembrace SymTouch, Onzetra Xsail, Sumavel DosePro, Zecuity
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.